Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose
Canadian Journal of Physiology and Pharmacology · 2023
DOI: 10.1139/cjpp-2022-0408 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2023. Verfasst von Mejo C Korah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Thrombosis Research, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, K…. Hauptthemen laut MEDLINE: Curcumin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben.
Abstract (Originalsprache)
Medicinal properties of curcumin are widely published. Previously, researchers used curcuminoid mixture comprising three chemical forms, out of which, the highest quantity is the most active molecule—dimethoxy curcumin (DMC). Reduced bioavailability, poor aqueous solubility, and quick hydrolytic degradation of DMC have projected challenges limiting its therapeutic value. However, selective conjugation of DMC with human serum albumin (HSA) enhances drug stability and solubility by several folds. Studies using animal models demonstrated potential anti-cancer/anti-inflammatory effects of DMCHSA; both studies showed results of local administration in peritoneal cavity and rabbit knee joint. DMC has prospects as intravenous therapeutic agent because carrier is HSA. However, before in vivo testing, important preclinical data required are toxicological safety and bioavailability of soluble forms of DMC. This study evaluated absorption, distribution, metabolism, and excretion of DMCHSA. Imaging technology and molecular analysis proved bio-distribution. The study also assessed the pharmacological safety of DMCHSA in mice in terms of its acute and sub-acute toxicity, complying with regulatory toxicology. Overall, the study demonstrated the safety pharmacology of DMCHSA upon intravenous infusion. This is a novel study establishing the safety of highly soluble and stable formulation of DMCHSA, qualifying it for intravenous administration and further efficacy evaluation in suitable disease models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Thrombosis Research, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
- Division of Laboratory Animal Science, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
- Department of Experimental Medicine, Faculty of Health and Medical Sciences, University of Copenhangen, Denmark.
- Division of Experimental Pathology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
- Division of Toxicology, Biomedical Technology Wing, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
Zitieren
APA
Korah, M. C., Harikrishnan, V. S., Deepa, S., Arya, A., Sabareeswaran, A., Mohanan, P. V., & Krishnan, L. K. (2023). Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2022-0408
Vancouver
Korah MC, Harikrishnan VS, Deepa S, Arya A, Sabareeswaran A, Mohanan PV, et al. Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose. Canadian Journal of Physiology and Pharmacology. 2023. doi:10.1139/cjpp-2022-0408
BibTeX
@article{Korah2023,
author = {Korah, Mejo C and Harikrishnan, V S and Deepa, S and Arya, Anil and Sabareeswaran, A and Mohanan, P V and Krishnan, Lissy K},
title = {Pharmacological safety of dimethoxy curcumin-human serum albumin conjugate for potential therapeutic purpose},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2023},
doi = {10.1139/cjpp-2022-0408}
}
EUVIMED